Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 21Squamous Cell Carcinoma of Head and Neck 18Urinary Bladder Neoplasms 8Oropharyngeal Neoplasms 8Uterine Cervical Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 6Neoplasms 6Colorectal Neoplasms 6Cholangiocarcinoma 6Carcinoma 6Neoplasm Metastasis 5Mesothelioma, Malignant 5Endometrial Neoplasms 5Biliary Tract Neoplasms 5Neoplasms by Site 4Nasopharyngeal Carcinoma 4Mouth Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Squamous Cell 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Medulloblastoma 3Laryngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Tongue Neoplasms 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Neoplasms × Cisplatin × 30 days × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡